Description

Simple

A medication used as part of a test for diagnosing prostate cancer.

Clinical

A monoclonal anti-prostate specific membrane antigen antibody used in imaging kits to target radioactive agents to malignant prostate tissue.

Overview

Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide [Indium In-111] during imaging to evaluate the extent of prostate cancer.

Pharmacology

Indication

For diagnosis of prostate cancer and detection of intra-pelvic metastases.

Pharmacodynamic

Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors.

Mechanism of action

Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

4 ± 2.1 L

Clearance

42 +/- 22 mL/hr

Half life

Information currently not available.

Route of elimination

Approximately 10% of the administered radioisotope dose is excreted in the urine during the 72 hours following intravenous infusion.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Capromab pendetide
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Abciximab
The risk or severity of adverse effects can be increased when Abciximab is combined with Capromab pendetide.
Abituzumab
The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Abituzumab.
Abrilumab
The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Abrilumab.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Capromab pendetide.
Adecatumumab
The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Adecatumumab.
Aducanumab
The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Aducanumab.
Afelimomab
The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Afelimomab.
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Capromab pendetide.
Alirocumab
The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Alirocumab.
Amatuximab
The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Amatuximab.
AMG 108
The risk or severity of adverse effects can be increased when Capromab pendetide is combined with AMG 108.
Anetumab ravtansine
The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Anetumab ravtansine.
Anifrolumab
The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Anifrolumab.
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Anthrax immune globulin human.
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Antithymocyte immunoglobulin (rabbit).
Apalutamide
Apalutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Apolizumab
The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Apolizumab.
Apomab
The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Apomab.
Ascrinvacumab
The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ascrinvacumab.
3 References
  1. 1 . Link Link
  2. 2 . Link Link
  3. 3 . Link Link